UCB SA Market Cap ($38.48 Billion)
Market Cap & Net Worth: UCB SA (UCB)
UCB SA market cap. UCB SA (BR:UCB) has a market capitalization of $38.48 Billion (€32.91 Billion) as of October 28, 2026. Listed on the BR stock exchange, this Belgium-based company holds position #699 globally and #4 in its home market, demonstrating a 30.95% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying UCB SA's stock price €268.70 by its total outstanding shares 190662572 (190.66 Million).
UCB SA Market Cap History (2015–2026)
UCB SA market cap history from 2015 to 2026. Data shows growth from $16.82 Billion to $59.89 Billion (14.04% CAGR). Check UCB stock price for real-time trading data and today's change.
Index Memberships
UCB SA is a constituent of 6 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
BEL-20 INDEX
BEL20
|
$378.22 Billion | 10.17% | #4 of 20 |
|
BEL-20 INDEX
BFX
|
$378.22 Billion | 10.17% | #4 of 20 |
|
BEL All Share
BSPT
|
$835.40 Billion | 4.61% | #7 of 108 |
|
STOXX Europe Large 200 EUR Price
LCXP
|
$7.23 Trillion | 0.53% | #53 of 182 |
|
STOXX Europe Large 200 Net Return
LCXR
|
$7.23 Trillion | 0.53% | #53 of 182 |
|
EuroNext 100
N100
|
$3.62 Trillion | 1.06% | #27 of 97 |
Weight: UCB SA's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
UCB SA Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how UCB SA's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Also see UCB SA cash conversion from operations for how efficiently the company converts equity into cash flow.
Latest Price to Sales (P/S) Ratio
6.87x
UCB SA's market cap is 6.87 times its annual revenue
Latest Price to Earnings (P/E) Ratio
34.14x
UCB SA's market cap is 34.14 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $12.46 Billion | $4.15 Billion | $520.00 Million | 3.00x | 23.96x |
| 2017 | $13.69 Billion | $4.47 Billion | $753.00 Million | 3.06x | 18.18x |
| 2018 | $14.95 Billion | $4.63 Billion | $800.00 Million | 3.23x | 18.69x |
| 2019 | $15.05 Billion | $4.91 Billion | $792.00 Million | 3.06x | 19.00x |
| 2020 | $18.12 Billion | $5.35 Billion | $732.00 Million | 3.39x | 24.76x |
| 2021 | $21.78 Billion | $5.78 Billion | $1.06 Billion | 3.77x | 20.58x |
| 2022 | $16.09 Billion | $5.52 Billion | $418.00 Million | 2.92x | 38.50x |
| 2023 | $17.45 Billion | $5.25 Billion | $343.00 Million | 3.32x | 50.88x |
| 2024 | $42.84 Billion | $6.15 Billion | $1.06 Billion | 6.96x | 40.23x |
| 2025 | $53.19 Billion | $7.74 Billion | $1.56 Billion | 6.87x | 34.14x |
Competitor Companies of UCB by Market Capitalization
Companies near UCB SA in the global market cap rankings as of October 28, 2026. See UCB SA net asset quality index to understand what proportion of total assets are financed by equity.
Key companies related to UCB SA by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #182 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #370 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #418 globally with a market cap of $67.55 Billion USD ( AU$95.47 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #497 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #182 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $521.03 |
| #370 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $816.10 |
| #418 | CSL Ltd | AU:CSL | $67.55 Billion | AU$196.78 |
| #497 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $207.97 |
Market Capitalization of UCB SA (2015–2026)
Market capitalization of UCB SA from 2015 to today. Between 2015 and today, UCB SA's market cap moved from $16.82 Billion to $ 59.89 Billion, with a yearly change of 14.04%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €59.89 Billion | +12.62% |
| 2025 | €53.19 Billion | +24.14% |
| 2024 | €42.84 Billion | +145.47% |
| 2023 | €17.45 Billion | +8.44% |
| 2022 | €16.09 Billion | -26.09% |
| 2021 | €21.78 Billion | +20.17% |
| 2020 | €18.12 Billion | +20.43% |
| 2019 | €15.05 Billion | +0.65% |
| 2018 | €14.95 Billion | +9.22% |
| 2017 | €13.69 Billion | +9.85% |
| 2016 | €12.46 Billion | -25.94% |
| 2015 | €16.82 Billion | -- |
End of Day Market Cap According to Different Sources
On Oct 28th, 2026 the market cap of UCB SA was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $38.48 Billion USD |
| MoneyControl | $38.48 Billion USD |
| MarketWatch | $38.48 Billion USD |
| marketcap.company | $38.48 Billion USD |
| Reuters | $38.48 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About UCB SA
UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company offers Cimzia for ankylosing spondylitis (AS), axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, polyarticular juvenile idiopathic arthritis, and rheumatoid arthritis; Vimpat, Keppra, … Read more